BiomX Investor Relations Material
Latest events
Q2 2024
BiomX
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from BiomX Inc
Access all reports
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
PHGE
Country
🇺🇸 United States